[HTML][HTML] Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non …
M Di Maio, NB Leighl, C Gallo, R Feld… - Journal of Thoracic …, 2012 - Elsevier
Introduction: The TORCH (Tarceva or Chemotherapy) trial randomized patients with
advanced non–small-cell lung cancer to first-line erlotinib followed by second-line …
advanced non–small-cell lung cancer to first-line erlotinib followed by second-line …
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non …
M Di Maio, NB Leighl, C Gallo, R Feld… - JOURNAL OF …, 2012 - iris.unina.it
INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with
advanced non-small-cell lung cancer to first-line erlotinib followed by second-line …
advanced non-small-cell lung cancer to first-line erlotinib followed by second-line …
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non …
M Di Maio, N Leighl, C Gallo, R Feld… - JOURNAL OF …, 2012 - sfera.unife.it
Abstract INTRODUCTION: The TORCH (Tarceva or Chemotherapy) trial randomized
patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second …
patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second …
[引用][C] Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non …
M DI MAIO, N Leighl, C Gallo, R Feld… - JOURNAL OF …, 2012 - iris.unito.it
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell …
M Di Maio, NB Leighl, C Gallo, R Feld, F Ciardiello… - 2012 - pubmed.ncbi.nlm.nih.gov
Introduction The TORCH (Tarceva or Chemotherapy) trial randomized patients with
advanced non-small-cell lung cancer to first-line erlotinib followed by second-line …
advanced non-small-cell lung cancer to first-line erlotinib followed by second-line …
[引用][C] Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced …
M Di Maio, NB Leighl, C Gallo, R Feld… - Journal of Thoracic …, 2012 - cir.nii.ac.jp
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by
Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer …
Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer …
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non …
M Di Maio, NB Leighl, C Gallo, R Feld… - Journal of Thoracic …, 2012 - jto.org
Introduction: The TORCH (Tarceva or Chemotherapy) trial randomized patients with
advanced non–small-cell lung cancer to first-line erlotinib followed by second-line …
advanced non–small-cell lung cancer to first-line erlotinib followed by second-line …
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell …
M Di Maio, NB Leighl, C Gallo, R Feld… - JOURNAL OF …, 2012 - iris.unime.it
he TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-
cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus …
cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus …
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell …
M Di Maio, NB Leighl, C Gallo, R Feld… - JOURNAL OF …, 2012 - air.unimi.it
Abstract INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized
patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second …
patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second …
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell …
M Di Maio, NB Leighl, C Gallo, R Feld… - Journal of Thoracic …, 2012 - europepmc.org
Methods QoL was assessed at baseline and every 3 weeks during first-line, using European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 …
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 …